Ipsen SA (IPN)-Financial and Strategic SWOT Analysis Review
August 2017
65
About the Report
About the Report
Ipsen SA (IPN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description-A detailed description of the company's operations and business divisions.
Corporate strategy-Analyst's summarization of the company's business strategy.
SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history-Progression of key events associated with the company.
Major products and services-A list of major products, services and brands of the company.
Key competitors-A list of key competitors to the company.
Key employees-A list of the key executives of the company.
Executive biographies-A brief summary of the executives' employment history.
Key operational heads-A list of personnel heading key departments/functions.
Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities-A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Ipsen SA (Ipsen) is a global specialty biotechnology company that manufactures and distributes drugs for the treatment of cancer and endocrine and neurological diseases. The company's portfolio of therapies focus at treating neuroendocrine tumors, prostate, bladder and kidney cancer, pituitary diseases, growth disorders precocious puberty, spasticity, cervical dystonia, hemifacial spasm, blepharospasm, gastrointestinal disorders, neurodegenerative pathologies, gout and other diseases. It has research and development facilities in Les Ulis, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France. Ipsen is headquartered in Paris, France.
Ipsen SA Key Recent Developments
Jul 27,2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017
Jun 01,2017: Ipsen To Present New Data of Investigational Compound Ga-OPS201 at ASCO in Line with its Continued Commitment to Oncology Research
Apr 27,2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1
Apr 14,2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer
Mar 02,2017: Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Ipsen SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1-About the Company 6
Ipsen SA-Key Facts 6
Ipsen SA-Key Employees 7
Ipsen SA-Key Employee Biographies 9
Ipsen SA-Major Products and Services 10
Ipsen SA-History 12
Ipsen SA-Company Statement 13
Ipsen SA-Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Affiliate 16
Joint Venture 16
Section 2-Company Analysis 17
Ipsen SA-Business Description 17
Ipsen SA-Corporate Strategy 18
Ipsen SA-SWOT Analysis 19
SWOT Analysis-Overview 19
Ipsen SA-Strengths 19
Ipsen SA-Weaknesses 20
Ipsen SA-Opportunities 21
Ipsen SA-Threats 23
Ipsen SA-Key Competitors 24
Section 3-Company Financial Ratios 25
Financial Ratios-Capital Market Ratios 25
Financial Ratios-Annual Ratios 26
Performance Chart 29
Financial Performance 29
Financial Ratios-Interim Ratios 30
Financial Ratios-Ratio Charts 31
Section 4-Company's Lifesciences Financial Deals and Alliances 32
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33
Ipsen SA, Recent Deals Summary 34
Section 5-Company's Recent Developments 35
Jul 27, 2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017 35
Jun 01, 2017: Ipsen To Present New Data of Investigational Compound Ga-OPS201 at ASCO in Line with its Continued Commitment to Oncology Research 43
Apr 27, 2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1 44
Apr 14, 2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer 47
Mar 02, 2017: Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care 48
Feb 23, 2017: Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017 49
Feb 06, 2017: Ipsen announces appointment of Dr. Sotirios G. Stergiopoulos as Head of Global Medical Affairs 57
Jan 20, 2017: Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises 58
Dec 12, 2016: Ipsen announces departure of EVP of R&D and chief scientific officer 59
Dec 12, 2016: Claude Bertrand to step down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen 60
Section 6-Appendix 61
Methodology 61
Ratio Definitions 61
About GlobalData 65
Contact Us 65
Disclaimer 65
List of Figure
List of Figures
Ipsen SA, Performance Chart (2012-2016) 29
Ipsen SA, Ratio Charts 31
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 33
List of Table
List of Tables
Ipsen SA, Key Facts 6
Ipsen SA, Key Employees 7
Ipsen SA, Key Employee Biographies 9
Ipsen SA, Major Products and Services 10
Ipsen SA, History 12
Ipsen SA, Subsidiaries 14
Ipsen SA, Affiliate 16
Ipsen SA, Joint Venture 16
Ipsen SA, Key Competitors 24
Ipsen SA, Ratios based on current share price 25
Ipsen SA, Annual Ratios 26
Ipsen SA, Annual Ratios (Cont...1) 27
Ipsen SA, Annual Ratios (Cont...2) 28
Ipsen SA, Interim Ratios 30
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33
Ipsen SA, Recent Deals Summary 34
Currency Codes 61
Capital Market Ratios 61
Equity Ratios 62
Profitability Ratios 62
Cost Ratios 63
Liquidity Ratios 63
Leverage Ratios 64
Efficiency Ratios 64
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.